Press Releases

Press Releases

All Releases
Aug 02, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced the election of Ian F. Smith , Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, to its Board of Directors, effective immediately. Mr. Smith has also been elected the Chair of the
Jul 25, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its second quarter 2016 financial results on Wednesday, August 3, 2016 . Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m.
Jun 20, 2016
- $30 Million Milestone Triggered by Reaching Final Enrollment Goal in the Third Phase 3 Trial in the Fovista ® Program - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced the completion of patient recruitment in its Phase 3 trial of Fovista ®
May 31, 2016
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 37 th Annual Global Healthcare Conference in Rancho
May 04, 2016
- Conference Call and Webcast Today, May 4 th , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on the Company's business and product development programs.
Apr 28, 2016
- Globally Recognized Innovator and Distinguished Scholar in the Diagnosis and Treatment of Retinal Disorders - - Brings Extensive Organizational and Leadership Experience - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) announced today the appointment of Carmen A.
Apr 26, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2016 financial results on Wednesday, May 4, 2016 . Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m.
Mar 08, 2016
Webcast Available Through Ophthotech Website NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Global Healthcare Conference 2016 in
Feb 24, 2016
- Conference Call and Webcast Today, February 24 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the fourth quarter and full year ended December 31, 2015 and provided an update on the Company's business and product
Feb 18, 2016
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the RBC Capital Markets Healthcare Conference
Feb 17, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its fourth quarter and year ended December 31, 2015 financial results on Wednesday, February 24, 2016 . Following the announcement, Ophthotech's management team will host a live conference call
Feb 03, 2016
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the LEERINK Partners 5th Annual Global
Jan 27, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura ® (avacincaptad pegol sodium), an inhibitor of complement factor C5, in patients with geographic atrophy, an advanced form of dry
Jan 06, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced the appointment of David E. Redlick to its Board of Directors effective immediately. David Redlick recently retired as a Partner in the Corporate Practice Group at Wilmer Cutler Pickering Hale and Dorr LLP
Jan 05, 2016
Michael G. Atieh to Retire as Executive Vice President and Chief Financial and Business Officer; Transition Expected at End of First Quarter 2016 - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) today announced that Glenn P. Sblendorio, a leading industry veteran, has agreed
Jan 04, 2016
Webcast Available Through Ophthotech Website NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 34th Annual J.P.
Dec 02, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Oppenheimer 26th Annual Healthcare
Dec 01, 2015
- Webcast to Begin at 8:30 a.m. Eastern Time - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that the Company will host a live webcast in conjunction with its Research and Development (R&D) Investor Day on Thursday, December 3, 2015 , beginning at 8:30 a.m. ET.
Nov 12, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 2015 Stifel Healthcare Conference in New